Drug Trial Radar · NCT03563144
QUILT-3.088: NANT Pancreatic Cancer Vaccine
Last checked: Nov 20, 2026Latest source record: Feb 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Aug 2018
Primary completion
Dec 30, 2019
Study completion Feb 9, 2022
Sponsor
- Lead sponsor
- ImmunityBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients with Metastatic Pancreatic Cancer.
Conditions
- Metastatic Pancreatic Cancer
Interventions
GemcitabineDrug
Gemcitabine is a type of chemotherapy medication used to interfere with the cancer cells' ability to grow and divide.
Nab-paclitaxelDrug
NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor. Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.
Aldoxorubicin HClDrug
Albumin-binding prodrug of doxorubicin HCl
ALT-803Biological
Recombinant human super agonist interleukin-15 (IL-15) complex
ETBX-011Biological
Ad5 \[E1-, E2b-\]-CEA
ETBX-021Biological
Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
ETBX-051Biological
Ad5 \[E1-, E2b-\]-Brachyury vaccine
ETBX-061Biological
Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
GI-4000Biological
Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
GI-6207Biological
CEA yeast vaccine
GI-6301Biological
Brachyury yeast vaccine
haNKBiological
NK-92 \[CD16.158V, ER IL-2\]
AvelumabDrug
Avelumab
BevacizumabDrug
Bevacizumab
CapecitabineDrug
Capecitabine
CyclophosphamideDrug
2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
5-FluorouracilDrug
5-fluoro-2,4 (1H,3H)-pyrimidinedione
LeucovorinDrug
L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
OxaliplatinDrug
Oxaliplatin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free SurvivalTime frame: 12 mths
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chan Soon-Shiong Institute for Medicine
El Segundo, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.